Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Respiratory System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Respiratory System Neoplasm

Cancer Family

Respiratory System Neoplasm

CI-CAN-00000049Explore in graph →

Non-malignant2,725 active trials51 approved drugs619 evidence items

NCIt: C3355
MeSH: D012142

Overview
Statistics
Survival
Genomics41
Variants & evidence619
Drugs128
Trials11608
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (473)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 30, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 76–100 of 473 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

GTV expert opinion: Optimizing photon radiation techniques and dosimetric constraints for locally advanced lung cancer with co-existing interstitial lung disease.
George J Li, Suresh Senan, Alexander V Louie · Radiother Oncol · Oct 1, 2026 · PMID 42785909 · candidate dictionary pubmed
GTV clinical scenario: protons vs photons in a patient with a second primary lung cancer and co-existing interstitial lung disease (ILD).
Sarah Bowen Jones, Aqeel Umar, Conal Hayton · Radiother Oncol · Oct 1, 2026 · PMID 42785907 · candidate dictionary pubmed
EVA1B promotes non-small cell lung cancer progression through an LRG1-associated mechanism.
Zhangzhou Huang, Haibo Wang, Kan Jiang et al. · 3 Biotech · Oct 1, 2026 · PMID 42781045 · candidate dictionary pubmed
Pharmacological considerations for prescribing of small molecule inhibitors in patients with non-small cell lung cancer.
Lotte M G Hulskotte, G D Marijn Veerman, Daan A C Lanser et al. · EClinicalMedicine · Oct 1, 2026 · PMID 42775005 · candidate dictionary pubmed
Predictors of lung cancer patients' behavioral intention to use virtual reality for treatment preparedness and shared decision-making: a Unified Theory of Acceptance and Use of Technology-based perception study.
Safa Elkefi, Steven K Feiner, Alicia K Matthews et al. · JAMIA Open · Oct 1, 2026 · PMID 42798801 · candidate dictionary pubmed
Long-term exposure to wildfire-related PM2·5 and overall survival of older patients with lung cancer: a retrospective, registry-based cohort study.
Min Zhang, Juan P Wisnivesky, Minghao Qiu et al. · Lancet Oncol · Oct 1, 2026 · PMID 42743939 · candidate

Showing 76–100 of 473 publications

← Previous
1
2
3
4
5
…
19
Next →

dictionary

Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial.

Marloes J Hassing, Nicole E Billingy, Corina J G van den Hurk et al. · Lancet Oncol · Oct 1, 2026 · PMID 42727592 · candidate dictionary pubmed

Intratumoral microbiota in the growth of CRC and lung cancer: Comprehensive insights from etiology to therapy.

Yicheng Wang, Jixiang Li, Xuxu Du et al. · iScience · Sep 18, 2026 · PMID 42668654 · candidate dictionary pubmed

EGFR T790M resistance mutation in non small-cell lung carcinoma.

· Clin Chim Acta · 2015 · PMID 25668228 · validated civic_curation pubmed

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

· N Engl J Med · 2010 · PMID 20979469 · validated civic_curation pubmed

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

· N Engl J Med · 2013 · PMID 23724913 · validated civic_curation pubmed

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

· N Engl J Med · 2014 · PMID 25470694 · validated civic_curation pubmed

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

· Lancet Oncol · 2016 · PMID 26708155 · validated civic_curation pubmed

Osimertinib: First Global Approval.

· Drugs · 2016 · PMID 26729184 · validated civic_curation pubmed

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

· N Engl J Med · 2017 · PMID 27959700 · validated civic_curation pubmed

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

· Oncologist · 2014 · PMID 24868098 · validated civic_curation pubmed

Afatinib: first global approval.

· Drugs · 2013 · PMID 23982599 · validated civic_curation pubmed

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

· JAMA · 2017 · PMID 28492898 · validated civic_curation pubmed

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.

· Ann Oncol · 2019 · PMID 30980071 · validated civic_curation pubmed

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

· N Engl J Med · 2017 · PMID 28586279 · validated civic_curation pubmed

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

· Lancet Oncol · 2017 · PMID 28602779 · validated civic_curation pubmed

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

· Lancet · 2017 · PMID 28501140 · validated civic_curation pubmed

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

· N Engl J Med · 2021 · PMID 34096690 · validated civic_curation pubmed

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.

· J Clin Oncol · 2020 · PMID 32780660 · validated civic_curation pubmed

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

· Lancet Oncol · 2020 · PMID 31838015 · validated civic_curation pubmed